Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study of APL-1202 in NMIBC Patients Who Are Resistant to One Induction Course of BCG Treatment

Next Previous
Trial Profile

A Phase Ib Study of APL-1202 in NMIBC Patients Who Are Resistant to One Induction Course of BCG Treatment

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BCG (Primary) ; Nitroxoline (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Adverse reactions
  • Acronyms NMIBC
  • Sponsors Asieris Pharmaceuticals

Most Recent Events

  • 16 Jul 2020 Status changed from active, no longer recruiting to completed.
  • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
  • 21 Jun 2019 According to an Asieris Pharmaceuticals media release, John P. Sfakianos, MD, (Assistant Professor of Icahn School of Medicine at Mount Sinai) is the leading investigator of this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top